- 文献引用 : 3
|Application ||WB, IF, IHC-P, E|
|Reactivity||Human, Mouse, Monkey, Rat|
|Other Names||Pyruvate kinase PKM, Cytosolic thyroid hormone-binding protein, CTHBP, Opa-interacting protein 3, OIP-3, Pyruvate kinase 2/3, Pyruvate kinase muscle isozyme, Thyroid hormone-binding protein 1, THBP1, Tumor M2-PK, p58, PKM, OIP3, PK2, PK3, PKM2|
|Target/Specificity||This Pyruvate Kinase (PKM2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 476-505 amino acids from the C-terminal region of human Pyruvate Kinase (PKM2).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Pyruvate Kinase (PKM2) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||OIP3, PK2, PK3, PKM2|
|Function||Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP. Stimulates POU5F1-mediated transcriptional activation. Plays a general role in caspase independent cell death of tumor cells. The ratio betwween the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production. The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival.|
|Cellular Location||Cytoplasm. Nucleus. Note=Translocates to the nucleus in response to different apoptotic stimuli. Nuclear translocation is sufficient to induce cell death that is caspase independent, isoform-specific and independent of its enzymatic activity|
|Tissue Location||Specifically expressed in proliferating cells, such as embryonic stem cells, embryonic carcinoma cells, as well as cancer cells.|
Author : Balogh E1,Veale DJ2,McGarry T3,Orr C2,Szekanecz Z1,Ng CT4,5,Fearon U3,Biniecka M6.
Arthritis Res Ther. 2018 May 29;20(1):95. doi: 10.1186/s13075-018-1592-1.
Author : McGarry T1,2,Biniecka M2,Gao W2,Cluxton D3,Canavan M1,2,Wade S1,Wade S1,2,Gallagher L2,Orr C2,Veale DJ2,Fearon U1.
Sci Rep. 2017 Feb 22;7:43165. doi: 10.1038/srep43165.
Author : Kienzl K, Sarg B, Golderer G, Obrist P, Werner ER, Werner-Felmayer G, Lindner H, Maglione M, Schneeberger S, Margreiter R, Brandacher G.
Transplantation. 2009 Aug 27;88(4):553-60. doi: 10.1097/TP.0b013e3181b119b1.
Provided below are standard protocols that you may find useful for product applications.
There are 4 isozymes of pyruvate kinase in mammals: L, R, M1 and M2. PKM2 is a pyruvate kinase that catalyzes the production of phosphoenolpyruvate from pyruvate and ATP. This protein has been shown to interact with thyroid hormone, and thus may mediate cellular metabolic effects induced by thyroid hormones. This protein has been found to bind Opa protein, a bacterial outer membrane protein involved in gonococcal adherence to and invasion of human cells, suggesting a role of this protein in bacterial pathogenesis.
References for protein:
1.Williams, J.M., et al., Mol. Microbiol. 27(1):171-186 (1998).
2.Gress, T.M., et al., Oncogene 13(8):1819-1830 (1996).
3.Kato, H., et al., Proc. Natl. Acad. Sci. U.S.A. 86(20):7861-7865 (1989).
4.Tsutsumi, H., et al., Genomics 2(1):86-89 (1988).
5.Tani, K., et al., Gene 73(2):509-516 (1988).
References for MCF7 cell line:
1.Soule, HD; Vazquez J; Long A; Albert S; Brennan M. (1973). "A human cell line from a pleural effusion derived from a breast carcinoma". Journal of the National Cancer Institute 51 (5): 1409–1416. [PMID 4357757].
2.Levenson, AS; Jordan VC. (1997). "MCF-7: the first hormone-responsive breast cancer cell line". Cancer Research 57 (15): 3071–3078. [PMID 9242427].
3.Lacroix, M; Leclercq G. (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Research and Treatment 83 (3): 249–289.[PMID 14758095].